Literature DB >> 24216242

Challenges of pediatric formulations: a FDA science perspective.

Abhay Gupta1, Mansoor A Khan.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24216242     DOI： 10.1016/j.ijpharm.2013.08.064

Source DB:  PubMed          Journal:  Int J Pharm        ISSN： 0378-5173            Impact factor:   5.875


× No keyword cloud information.
  3 in total

1.  Development of a Pediatric Mini-Tablet Formulation for Expedited Preclinical Studies.

Authors:  Monika Lavan; Xueqi Wang; Robyn McCain; Amber Jannasch; Bruce Cooper; Scott Hostetler; Stephen Byrn; Gregory Knipp
Journal:  AAPS PharmSciTech       Date:  2021-01-08       Impact factor: 3.246

2.  Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered.

Authors:  Kristine Svinning Valeur; Helle Holst; Karel Allegaert
Journal:  Pharmaceut Med       Date:  2018-08-10

3.  Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial.

Authors:  D T Wademan; L Busakwe; T J Nicholson; M van der Zalm; M Palmer; J Workman; A Turkova; A M Crook; M J Thomason; D M Gibb; J Seeley; A Hesseling; G Hoddinott
Journal:  Int J Tuberc Lung Dis       Date:  2019-12-01       Impact factor: 2.373
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.